Lilly's tirzepatide-eloralintide combo shows superior weight loss but higher discontinuation, adding pipeline optionality with tolerability caveat.

What happened

Eli Lilly announced Phase 3 results showing that tirzepatide combined with eloralintide achieved up to 23.3% weight loss after 48 weeks, notably higher than Zepbound alone. However, the combination also had significantly higher discontinuation rates, signaling potential tolerability issues that could limit real-world adherence. This data adds to Lilly's next-wave obesity pipeline, which already includes eloralintide and retatrutide, but it remains early-stage and not yet factored into near-term revenue. The master report maintained a WAIT rating on LLY with a $1,146 share price, driven by concerns over oral adoption (Foundayo) and Medicare access execution rather than pipeline depth. While the news confirms Lilly's innovation capacity, it does not address the key near-term catalysts of Foundayo ramp and pricing pressure, leaving the investment thesis largely unchanged.

Implication

The higher efficacy of the combination reinforces Lilly's ability to stay ahead in obesity treatment, but the higher discontinuation rate raises the bar for achieving durable real-world usage. Current valuation at ~38x earnings already assumes successful pipeline expansion, so this data alone is unlikely to move the stock without further evidence of tolerability and commercial preparation. The key near-term drivers remain Foundayo's script acceleration and Medicare Bridge uptake, which are more directly tied to 2026-2027 earnings than eloralintide. Investors should monitor subsequent data on the combination's tolerability profile and any signals on how Lilly plans to position it relative to Zepbound and retatrutide. Maintaining the WAIT rating is appropriate; consider adding on a pullback toward $1,000 or upon clearer evidence that oral and access execution are on track.

Thesis delta

The thesis remains WAIT. The new combination data modestly strengthens the long-term pipeline narrative but the discontinuation issue introduces a tolerability risk that could limit its eventual commercial impact. No changes to near-term catalysts or valuation assumptions.